Pegzilarginase is under clinical development by Aeglea BioTherapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Pegzilarginase’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 09 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Pegzilarginase Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Pegzilarginase overview

Pegzilarginase (AEB-1102) (AERase) is under development for the treatment of arginase I deficiency (Hyperargininemia), solid tumor, small cell lung cancer, cutaneous melanoma, uveal melanoma. It is administered intravenously. The drug candidate is a pegylated recombinant human arginase I. It is developed by substituting the cofactor manganese with cobalt. Recombinant arginase I act by degrading the amino acids arginine. It was under development for treatment of colon cancer, myelodysplastic syndrome, refractory and relapsed acute myeloid leukemia, hepatocellular carcinoma.

Aeglea BioTherapeutics overview

Aeglea BioTherapeutics (Aeglea) is a biotechnology company. The company develops and commercializes human enzymes for the treatment of cancer and rare genetic diseases. The company’s lead product pipeline includes pegzilarginase (AEB1102), is used for the treatment of arginase deficiency. It also develops AGLE-177, for treating classical homocystinuria, a rare disease cause due to hereditary genetic deficiency; AGLE-324, for treating cystinuria. Aeglea also provides enzyme solutions to treat diseases with unmet medical needs. The company works in partnership with research institutions, healthcare providers and pharmaceutical companies. It caters its products across the US and the UK. Aeglea is headquartered in Austin, Texas, the US.

Quick View Pegzilarginase LOA Data

Report Segments
  • Innovator
Drug Name
  • Pegzilarginase
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Genetic Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.